CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues:
Revenue from contract with customer	$ 16,071.7	$ 8,497.1	$ 6,557.6
Expenses:
Research and development	2,908.1	2,735.0	2,450.0
Selling, general, and administrative	1,824.9	1,346.0	1,341.9
Other operating (income) expense, net	(45.6)	(280.4)	(209.2)
Total expenses	7,124.9	4,920.5	4,347.8
Income from operations	8,946.8	3,576.6	2,209.8
Other income (expense):
Other income (expense), net	436.3	290.7	249.5
Interest expense	(57.3)	(56.9)	(30.2)
Total other income (expense)	379.0	233.8	219.3
Income before income taxes	9,325.8	3,810.4	2,429.1
Income tax expense	1,250.5	297.2	313.3
Net income	$ 8,075.3	$ 3,513.2	$ 2,115.8
Net income per share - basic (in dollars per share)	$ 76.40	$ 32.65	$ 19.38
Net income per share - diluted (in dollars per share)	$ 71.97	$ 30.52	$ 18.46
Weighted average shares outstanding - basic (in shares)	105.7	107.6	109.2
Weighted average shares outstanding - diluted (in shares)	112.2	115.1	114.6
Statements of Comprehensive Income
Net income	$ 8,075.3	$ 3,513.2	$ 2,115.8
Other comprehensive income (loss), net of tax:
Unrealized (loss) gain on debt securities	(56.4)	9.1	35.9
Unrealized gain (loss) on cash flow hedges	0.9	(0.9)	(2.5)
Comprehensive income	8,019.8	3,521.4	2,149.2
Net product sales
Revenues:
Revenue from contract with customer	12,117.2	5,567.6	4,834.4
Expenses:
Cost of goods sold and of collaboration and contract manufacturing	1,773.1	491.9	362.3
Other revenue
Revenues:
Revenue from contract with customer	281.2	557.0	174.0
Cost of collaboration and contract manufacturing
Expenses:
Cost of goods sold and of collaboration and contract manufacturing	664.4	628.0	402.8
Sanofi | Collaboration revenue
Revenues:
Revenue from contract with customer	1,902.2	1,186.4	403.6
Other collaboration | Collaboration revenue
Revenues:
Revenue from contract with customer	$ 1,771.1	$ 1,186.1	$ 1,145.6